Dx & Vx Overview

  • Year Founded
  • 2001

Year Founded

  • Status
  • Public

  • Employees
  • 89

Employees

  • Stock Symbol
  • 180400

Stock Symbol

  • Investments
  • 3

  • Share Price
  • $1.54
  • (As of Monday Closing)

Dx & Vx General Information

Description

Dx & Vx Co Ltd is a bio-healthcare company operating in the following business segments: Medical Diagnosis, Healthcare, and New Drug Development. The majority of its revenue is generated from the Healthcare segment, which utilizes diagnostic technology to provide integrated biohealthcare solutions for microbiome-based diseases, and offers health functional foods for prevention, over-the-counter and prescription drugs for treatment, and lifestyle and hygiene products for management. The Medical Diagnosis segment provides preimplantation, prenatal, neonatal, and adult genomic testing and microbiome analysis services, and the New Drug Development business is involved in the research and development of COVID vaccines and treatment, microbiome respiratory vaccine, and mRNA anticancer vaccine.

Contact Information

Website
www.dxvx.com
Formerly Known As
Mg med, CancerRop
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 10th Floor 234, Digital-ro
  • Geumcheon-gu
  • Seoul
  • South Korea
+82
Primary Industry
Drug Discovery
Stock Exchange
KRX
Vertical(s)
Corporate Office
  • 10th Floor 234, Digital-ro
  • Geumcheon-gu
  • Seoul
  • South Korea
+82

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Dx & Vx Stock Performance

As of 16-Nov-2026, Dx & Vx’s stock price is $1.54. Its current market cap is $152M with 98.4M shares.

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.54 $1.55 $0.89 - $3.64 $152M 98.4M 52.9K -$0.27

Dx & Vx Financials Summary

As of 30-Jun-2026, Dx & Vx has a trailing 12-month revenue of $18.1M.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 112,979 135,752 79,981 161,172
Revenue 18,070 20,628 24,880 31,545
EBITDA (16,501) (19,382) (36,305) (17,357)
Net Income (17,377) (20,405) (34,471) (21,020)
Total Assets 69,665 107,551 49,124 77,549
Total Debt 9,489 33,325 29,046 30,902
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Dx & Vx Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Dx & Vx‘s full profile, request access.

Request a free trial

Dx & Vx Patents

Dx & Vx Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026205991-A1 Novel compounds with glp-1 receptor agonist activity Pending 27-Mar-2025
WO-2026205992-A1 Novel probiotic culture having preventive and therapeutic activity against stress, depression, and hearing loss Pending 27-Mar-2025
EP-4831287-A1 Novel circular rna synthesis method using rna ligase Pending 18-Dec-2023
US-11865480-B2 Nucleic acid purification device and nucleic acid purification method Active 07-May-2019
US-20200353393-A1 Nucleic acid purification device and nucleic acid purification method Active 07-May-2019 B01D39/2065
To view Dx & Vx’s complete patent history, request access »

Dx & Vx Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Dx & Vx Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Dx & Vx‘s full profile, request access.

Request a free trial

Dx & Vx Investments & Acquisitions (3)

Dx & Vx’s most recent deal was a Later Stage VC with Oxford Vacmedix for . The deal was made on 16-May-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Oxford Vacmedix 16-May-2025 Later Stage VC Drug Discovery
Korea Biopharmaceuticals 16-Sep-2022 Merger/Acquisition Drug Discovery
Oxford Cancer Biomarkers 08-May-2017 Later Stage VC Discovery Tools (Healthcare)
To view Dx & Vx’s complete investments and acquisitions history, request access »

Dx & Vx ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Healthcare

Industry

Rank

Percentile

Medical Devices

Subindustry

Rank

Percentile

To view Dx & Vx’s complete esg history, request access »

Dx & Vx Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Korea Biopharmaceuticals Chungbuk, South Korea 1995

Dx & Vx FAQs

  • When was Dx & Vx founded?

    Dx & Vx was founded in 2001.

  • Where is Dx & Vx headquartered?

    Dx & Vx is headquartered in Seoul, South Korea.

  • What is the size of Dx & Vx?

    Dx & Vx has 89 total employees.

  • What industry is Dx & Vx in?

    Dx & Vx’s primary industry is Drug Discovery.

  • Is Dx & Vx a private or public company?

    Dx & Vx is a Public company.

  • What is Dx & Vx’s stock symbol?

    The ticker symbol for Dx & Vx is 180400.

  • What is the current stock price of Dx & Vx?

    As of 16-Nov-2026 the stock price of Dx & Vx is $1.54.

  • What is the current market cap of Dx & Vx?

    The current market capitalization of Dx & Vx is $152M.

  • What is Dx & Vx’s current revenue?

    The trailing twelve month revenue for Dx & Vx is $18.1M.

  • What is Dx & Vx’s annual earnings per share (EPS)?

    Dx & Vx’s EPS for 12 months was -$0.27.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process